Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.

Saved in:
Bibliographic Details
Title: Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.
Authors: Fong L; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California. Lawrence.Fong@ucsf.edu rmiller@corvuspharma.com., Hotson A; Corvus Pharmaceuticals, Burlingame, California., Powderly JD; Carolina BioOncology Institute, Huntersville, North Carolina., Sznol M; Yale University Cancer Center, Yale University, New Haven, Connecticut., Heist RS; Massachusetts General Hospital, Harvard University, Boston, Massachusetts., Choueiri TK; Dana- Farber Cancer Institute, Boston, Massachusetts., George S; Roswell Park Cancer Institute, Buffalo, New York., Hughes BGM; Royal Brisbane Hospital and University of Queensland, Herston, Brisbane, Queensland, Australia., Hellmann MD; Memorial Sloan Kettering Cancer Center, New York, New York., Shepard DR; Cleveland Clinic Foundation, Cleveland, Ohio., Rini BI; Cleveland Clinic Foundation, Cleveland, Ohio., Kummar S; Stanford University School of Medicine, Stanford, California., Weise AM; Karmanos Cancer Institute, Wayne State University, Detroit, Michigan., Riese MJ; Medical College of Wisconsin, Wauwatosa, Wisconsin., Markman B; Monash Health and Monash University, Melbourne, Clayton, Victoria, Australia., Emens LA; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania., Mahadevan D; University of Arizona Cancer Center, Tucson, Arizona., Luke JJ; University of Chicago Medical Center for Care and Discovery, Chicago, Illinois., Laport G; Corvus Pharmaceuticals, Burlingame, California., Brody JD; Icahn School of Medicine at Mount Sinai, New York, New York., Hernandez-Aya L; Washington University Siteman Cancer Center, St Louis, Missouri., Bonomi P; Rush University Medical Center, Chicago, Illinois., Goldman JW; Ronald Reagan UCLA Medical Center, Los Angeles, California., Berim L; University of Nebraska Medical Center, Omaha, Nebraska., Renouf DJ; BC Cancer - Vancouver, Vancouver, British Columbia, Canada., Goodwin RA; The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada., Munneke B; Corvus Pharmaceuticals, Burlingame, California., Ho PY; Corvus Pharmaceuticals, Burlingame, California., Hsieh J; Corvus Pharmaceuticals, Burlingame, California., McCaffery I; Corvus Pharmaceuticals, Burlingame, California., Kwei L; Corvus Pharmaceuticals, Burlingame, California., Willingham SB; Corvus Pharmaceuticals, Burlingame, California., Miller RA; Corvus Pharmaceuticals, Burlingame, California. Lawrence.Fong@ucsf.edu rmiller@corvuspharma.com.
Source: Cancer discovery [Cancer Discov] 2020 Jan; Vol. 10 (1), pp. 40-53. Date of Electronic Publication: 2019 Nov 15.
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2159-8290
DOI:10.1158/2159-8290.CD-19-0980